Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Inclusion Criteria: 1. Voluntary provision of informed consent. 2. Males or females aged 18-75. 3. Histological or cytologically confirmed NSCLC, metastatic or non-resectable (stage IIIB-Ⅳ). 4. At least one lesion can be measured by imaging. 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1. 6. Life expectancy ≥ 12 weeks. 7. None previous chemotherapy or targeted therapy(Arm:wild-type genotype). 8. Patients should be confirmed acquired EGFR T790M mutation and received adequate EGFR-TKI treatment(Arm:EGFR mutation). 9. Female of childbearing age must have a negative pregnancy test (serum or urine) within 7 days before enrolment. Exclusion Criteria: 1. Histological or cytologically confirmed small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC. 2. Diagnosed with other malignant diseases other than NSCLC within 5 years. 3. Have participated in other interventional clinical research treatments now or within 4 weeks. 4. Have previously received multi-targeted kinase inhibitors therapy. 5. Have active autoimmune diseases requiring systemic treatment within 2 years. 6. Received systemic glucocorticoid therapy or immunosuppressive therapy within 2 weeks. 7. Clinically uncontrollable pleural effusion/abdominal effusion. 8. Vaccinated vaccines or attenuated vaccines within 4 weeks before the group; 9. Pregnant or breastfeeding females. 10. Other serious hazards to the safety of patients.